Price Alert

REGENXBIO Inc. (RGNX)

NASDAQ: RGNX · Real-Time Price · USD

10.43

-0.15 (-1.42%)

At close: Oct 03, 2025, 3:59 PM

10.57

1.34%

After-hours: Oct 03, 2025, 05:46 PM EDT

REGENXBIO Statistics

Share Statistics

REGENXBIO has 50.51M shares outstanding. The number of shares has increased by 1.96% in one year.

Shares Outstanding	50.51M
Shares Change (YoY)	1.96%
Shares Change (QoQ)	0.25%
Owned by Institutions (%)	81.66%
Shares Floating	41.41M
Failed to Deliver (FTD) Shares	44,899
FTD / Avg. Volume	7.63%

Short Selling Information

The latest short interest is 5.07M, so 10.03% of the outstanding shares have been sold short.

Short Interest	5.07M
Short % of Shares Out	10.03%
Short % of Float	12.18%
Short Ratio (days to cover)	11.38

Valuation Ratios

The PE ratio is -1.69 and the forward PE ratio is -5.04. REGENXBIO's PEG ratio is 0.07.

PE Ratio	-1.69
Forward PE	-5.04
PS Ratio	4.59
Forward PS	1.9
PB Ratio	1.47
P/FCF Ratio	-2.18
PEG Ratio	0.07

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for REGENXBIO.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.69, with a Debt / Equity ratio of 0.32.

Current Ratio	2.69
Quick Ratio	2.69
Debt / Equity	0.32
Debt / EBITDA	-0.41
Debt / FCF	-0.47
Interest Coverage	-18.43

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$236.06K
Profits Per Employee	$-643.35K
Employee Count	353
Asset Turnover	0.18
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	0%

Stock Price Statistics

The stock price has increased by 7.3% in the last 52 weeks. The beta is 1.17, so REGENXBIO's price volatility has been higher than the market average.

Beta	1.17
52-Week Price Change	7.3%
50-Day Moving Average	8.99
200-Day Moving Average	8.23
Relative Strength Index (RSI)	63.02
Average Volume (20 Days)	588,396

Income Statement

In the last 12 months, REGENXBIO had revenue of 83.33M and earned -227.1M in profits. Earnings per share was -4.59.

Revenue	83.33M
Gross Profit	49.76M
Operating Income	-233.35M
Net Income	-227.1M
EBITDA	-198.23M
EBIT	-214.44M
Earnings Per Share (EPS)	-4.59

Full Income Statement

Balance Sheet

The company has 57.53M in cash and 82.03M in debt, giving a net cash position of -24.51M.

Cash & Cash Equivalents	57.53M
Total Debt	82.03M
Net Cash	-24.51M
Retained Earnings	-932.15M
Total Assets	581.03M
Working Capital	254.21M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -173.13M and capital expenditures -2.44M, giving a free cash flow of -175.56M.

Operating Cash Flow	-173.13M
Capital Expenditures	-2.44M
Free Cash Flow	-175.56M
FCF Per Share	-3.55

Full Cash Flow Statement

Margins

Gross margin is 59.72%, with operating and profit margins of -280.03% and -272.54%.

Gross Margin	59.72%
Operating Margin	-280.03%
Pretax Margin	-272.54%
Profit Margin	-272.54%
EBITDA Margin	-237.89%
EBIT Margin	-280.03%
FCF Margin	-210.69%

Dividends & Yields

RGNX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for RGNX is $24, which is 130.1% higher than the current price. The consensus rating is "Buy".

Price Target	$24
Price Target Difference	130.1%
Analyst Consensus	Buy
Analyst Count	7

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-1.69
Piotroski F-Score	3